Pharmacokinetic drug interactions in liver disease: An update

World Journal of Gastroenterology

Volumn 22, Issue 3, 2016, Pages 1260-1278

  Palatini, Pietro ^a   De Martin, Sara ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Enzyme induction; Enzyme inhibition; Liver disease; Pharmacokinetic interactions; Plasma protein binding

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; CONSTITUTIVE ANDROSTANE RECEPTOR; CYTOCHROME P450 1A2; CYTOCHROME P450 2E1; CYTOCHROME P450 3A1; CYTOCHROME P450 3A2; CYTOCHROME P450 3A4; DRUG METABOLIZING ENZYME; FARNESOID X RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PREGNANE X RECEPTOR; VITAMIN D RECEPTOR; CARRIER PROTEIN; CYTOCHROME P450 INDUCER; CYTOCHROME P450 INHIBITOR; ENZYME INHIBITOR; PROTEIN BINDING;

AEROBIC METABOLISM; COMPENSATED LIVER CIRRHOSIS; CREATININE CLEARANCE; DEMETHYLATION; DRUG DISPOSITION; DRUG ELIMINATION; DRUG INTERACTION; DRUG METABOLISM; DRUG TRANSFORMATION; DRUG UPTAKE; ENVIRONMENTAL FACTOR; ENZYME INACTIVATION; ENZYME INDUCTION; ENZYME INHIBITION; GENETIC POLYMORPHISM; HEPATIC CLEARANCE; HEPATIC EXTRACTION RATIO; HEREDITY; HUMAN; INTRINSIC CLEARANCE; LIGAND BINDING; LIVER CELL; LIVER CIRRHOSIS; LIVER DISEASE; LIVER DYSFUNCTION; LIVER FUNCTION; NONHUMAN; PHARMACOKINETICS; PLASMA CLEARANCE; PLASMA PROTEIN BINDING; PROTEIN EXPRESSION; REVIEW; SEVERE HEPATIC IMPAIRMENT; BIOTRANSFORMATION; COMPLICATION; DOSE CALCULATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ENZYMOLOGY; GENETICS; LIVER; LIVER DISEASES; LIVER FUNCTION TEST; METABOLISM; RISK ASSESSMENT; RISK FACTOR; TRANSPORT AT THE CELLULAR LEVEL;

BIOLOGICAL TRANSPORT; BIOTRANSFORMATION; CYTOCHROME P-450 ENZYME INDUCERS; CYTOCHROME P-450 ENZYME INHIBITORS; DRUG DOSAGE CALCULATIONS; DRUG INTERACTIONS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ENZYME INDUCTION; ENZYME INHIBITORS; HUMANS; LIVER; LIVER DISEASES; LIVER FUNCTION TESTS; MEMBRANE TRANSPORT PROTEINS; PHARMACOKINETICS; POLYMORPHISM, GENETIC; PROTEIN BINDING; RISK ASSESSMENT; RISK FACTORS;

EID: 84961305634     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v22.i3.1260     Document Type: Review

References (108)

1. Köhler GI, Bode-Böger SM, Busse R, Hoopmann M, Welte T, Böger RH. Drug-drug interactions in medical patients: effects of in-hospital treatment and relation to multiple drug use. Int J Clin Pharmacol Ther 2000; 38: 504-513 [PMID: 11097142]
2. Hohl CM, Dankoff J, Colacone A, Afilalo M. Polypharmacy, adverse drug-related events, and potential adverse drug interactions in elderly patients presenting to an emergency department. Ann Emerg Med 2001; 38: 666-671 [PMID: 11719747]
3. Leape LL, Bates DW, Cullen DJ, Cooper J, Demonaco HJ, Gallivan T, Hallisey R, Ives J, Laird N, Laffel G. Systems analysis of adverse drug events. ADE Prevention Study Group. JAMA 1995; 274: 35-43 [PMID: 7791256]
4. Buajordet I, Ebbesen J, Erikssen J, Brørs O, Hilberg T. Fatal adverse drug events: The paradox of drug treatment. J Intern Med 2001; 250: 327-341 [PMID: 11576320]
5. Müller F, Fromm MF. Transporter-mediated drug-drug interactions. Pharmacogenomics 2011; 12: 1017-1037 [PMID: 21787191 DOI: 10.2217/pgs.11.44]
6. Pirmohamed M, Park BK. Cytochrome P450 enzyme polymorphisms and adverse drug reactions. Toxicology 2003; 192: 23-32 [PMID: 14511900]
7. Teo YL, Ho HK, Chan A. Metabolism-related pharmacokinetic drug-drug interactions with tyrosine kinase inhibitors: current understanding, challenges and recommendations. Br J Clin Pharmacol 2015; 79: 241-253 [PMID: 25125025 DOI: 10.1111/ bcp.12496]
8. Adams DH, Ju C, Ramaiah SK, Uetrecht J, Jaeschke H. Mechanisms of immune-mediated liver injury. Toxicol Sci 2010; 115: 307-321 [PMID: 20071422 DOI: 10.1093/toxsci/kfq009]
9. Yu J, Ritchie TK, Mulgaonkar A, Ragueneau-Majlessi I. Drug disposition and drug-drug interaction data in 2013 FDA new drug applications: A systematic review. Drug Metab Dispos 2014; 42: 1991-2001 [PMID: 25271211 DOI: 10.1124/dmd.114.060392]
10. Obach RS, Walsky RL, Venkatakrishnan K, Houston JB, Tremaine LM. In vitro cytochrome P450 inhibition data and the prediction of drug-drug interactions: qualitative relationships, quantitative predictions, and the rank-order approach. Clin Pharmacol Ther 2005; 78: 582-592 [PMID: 16338274 DOI: 10.1016/ j.clpt.2005.09.004]
11. Zhang L, Zhang YD, Zhao P, Huang SM. Predicting drug-drug interactions: an FDA perspective. AAPS J 2009; 11: 300-306 [PMID: 19418230 DOI: 10.1208/s12248-009-9106-3]
12. Greenblatt DJ. In vitro prediction of clinical drug interactions with CYP3A substrates: we are not there yet. Clin Pharmacol Ther 2014; 95: 133-135 [PMID: 24448459 DOI: 10.1038/ clpt.2013.230]
13. Christensen H, Baker M, Tucker GT, Rostami-Hodjegan A. Prediction of plasma protein binding displacement and its implications for quantitative assessment of metabolic drug-drug interactions from in vitro data. J Pharm Sci 2006; 95: 2778-2787 [PMID: 16937340 DOI: 10.1002/jps.20733]
14. Cheng PY, Morgan ET. Hepatic cytochrome P450 regulation in disease states. Curr Drug Metab 2001; 2: 165-183 [PMID: 11469724]
15. Lee LS, Nafziger AN, Bertino JS. Evaluation of inhibitory drug interactions during drug development: genetic polymorphisms must be considered. Clin Pharmacol Ther 2005; 78: 1-6 [PMID: 16003286 DOI: 10.1016/j.clpt.2005.04.006]
16. Ma Q, Lu AY. Origins of individual variability in P4501A induction. Chem Res Toxicol 2003; 16: 249-260 [PMID: 12641424 DOI: 10.1021/tx0200919]
17. Tang C, Lin JH, Lu AY. Metabolism-based drug-drug interactions: what determines individual variability in cytochrome P450 induction? Drug Metab Dispos 2005; 33: 603-613 [PMID: 15673596 DOI: 10.1124/dmd.104.003236]
18. Palatini P, De Martin S, Pegoraro P, Orlando R. Enzyme inhibition and induction in liver disease. Curr Clin Pharmacol 2008; 3: 56-69 [PMID: 18690879]
19. Morgan DJ, McLean AJ. Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease. An update. Clin Pharmacokinet 1995; 29: 370-391 [PMID: 8582120]
20. Schuppan D, Afdhal NH. Liver cirrhosis. Lancet 2008; 371: 838-851 [PMID: 18328931 DOI: 10.1016/S0140-6736(08)60383-9]
21. Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. Lancet 2014; 383: 1749-1761 [PMID: 24480518 DOI: 10.1016/ S0140-6736(14)60121-5]
22. Gaba RC, Couture PM, Bui JT, Knuttinen MG, Walzer NM, Kallwitz ER, Berkes JL, Cotler SJ. Prognostic capability of different liver disease scoring systems for prediction of early mortality after transjugular intrahepatic portosystemic shunt creation. J Vasc Interv Radiol 2013; 24: 411-420, 420.e1-e4; quiz 421 [PMID: 23312989 DOI: 10.1016/j.jvir.2012.10.026]
23. Conn HO. A peek at the Child-Turcotte classification. Hepatology 1981; 1: 673-676 [PMID: 7308998]
24. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-649 [PMID: 4541913]
25. Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol 2008; 64: 1147-1161 [PMID: 18762933 DOI: 10.1007/s00228-008-0553-z]
26. Sinha V, Brendel K, Mayersohn M. A simplified isolated perfused rat liver apparatus: characterization and measurement of extraction ratios of selected compounds. Life Sci 2000; 66: 1795-1804 [PMID: 10809177]
27. Morgan ET. Impact of infectious and inflammatory disease on cytochrome P450-medi a t ed drug me t abol i sm and pharmacokinetics. Clin Pharmacol Ther 2009; 85: 434-438 [PMID: 19212314 DOI: 10.1038/clpt.2008.302]
28. Huet PM, Villeneuve JP, Fenyves D. Drug elimination in chronic liver diseases. J Hepatol 1997; 26 Suppl 2: 63-72 [PMID: 9204411]
29. Orlando R, Piccoli P, De Martin S, Padrini R, Floreani M, Palatini P. Cytochrome P450 1A2 is a major determinant of lidocaine metabolism in vivo: effects of liver function. Clin Pharmacol Ther 2004; 75: 80-88 [PMID: 14749694 DOI: 10.1016/ j.clpt.2003.09.007]
30. Orlando R, Padrini R, Perazzi M, De Martin S, Piccoli P, Palatini P. Liver dysfunction markedly decreases the inhibition of cytochrome P450 1A2-mediated theophylline metabolism by fluvoxamine. Clin Pharmacol Ther 2006; 79: 489-499 [PMID: 16678550 DOI: 10.1016/j.clpt.2006.01.012]
31. Gariépy L, Fenyves D, Kassissia I, Villeneuve JP. Clearance by the liver in cirrhosis. II. Characterization of propranolol uptake with the multiple-indicator dilution technique. Hepatology 1993; 18: 823-831 [PMID: 8406355]
32. Le Couteur DG, Fraser R, Hilmer S, Rivory LP, McLean AJ. The hepatic sinusoid in aging and cirrhosis: effects on hepatic substrate disposition and drug clearance. Clin Pharmacokinet 2005; 44: 187-200 [PMID: 15656697]
33. McLean AJ, Morgan DJ. Clinical pharmacokinetics in patients with liver disease. Clin Pharmacokinet 1991; 21: 42-69 [PMID: 1914341]
34. Hickey PL, Angus PW, McLean AJ, Morgan DJ. Oxygen supplementation restores theophylline clearance to normal in cirrhotic rats. Gastroenterology 1995; 108: 1504-1509 [PMID: 7729643]
35. Froomes PR, Morgan DJ, Smallwood RA, Angus PW. Comparative effects of oxygen supplementation on theophylline and acetaminophen clearance in human cirrhosis. Gastroenterology 1999; 116: 915-920 [PMID: 10092314]
36. Howden CW, Birnie GG, Brodie MJ. Drug metabolism in liver disease. Pharmacol Ther 1989; 40: 439-474 [PMID: 2646653]
37. Murray M. Mechanisms and significance of inhibitory drug interactions involving cytochrome P450 enzymes (review). Int J Mol Med 1999; 3: 227-238 [PMID: 10028046]
38. Thummel KE, Wilkinson GR. In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol 1998; 38: 389-430 [PMID: 9597161 DOI: 10.1146/ annurev.pharmtox.38.1.389]
39. Koley AP, Robinson RC, Markowitz A, Friedman FK. Drug-drug interactions: effect of quinidine on nifedipine binding to human cytochrome P450 3A4. Biochem Pharmacol 1997; 53: 455-460 [PMID: 9105395]
40. Zhou S, Yung Chan S, Cher Goh B, Chan E, Duan W, Huang M, McLeod HL. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet 2005; 44: 279-304 [PMID: 15762770]
41. Yasui-Furukori N, Saito M, Uno T, Takahata T, Sugawara K, Tateishi T. Effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes. J Clin Pharmacol 2004; 44: 1223-1229 [PMID: 15496639]
42. Eap CB, Lessard E, Baumann P, Brawand-Amey M, Yessine MA, O'Hara G, Turgeon J. Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans. Pharmacogenetics 2003; 13: 39-47 [PMID: 12544511]
43. Shah RR, Smith RL. Addressing phenoconversion: The Achilles' heel of personalized medicine. Br J Clin Pharmacol 2015; 79: 222-240 [PMID: 24913012 DOI: 10.1111/bcp.12441]
44. Morgan ET. Regulation of cytochrome P450 by inflammatory mediators: why and how? Drug Metab Dispos 2001; 29: 207-212 [PMID: 11181485]
45. Shah RR, Smith RL. Inflammation-induced phenoconversion of polymorphic drug metabolizing enzymes: hypothesis with implications for personalized medicine. Drug Metab Dispos 2015; 43: 400-410 [PMID: 25519488 DOI: 10.1124/dmd.114.061093]
46. Orlando R, Piccoli P, De Martin S, Padrini R, Palatini P. Effect of the CYP3A4 inhibitor erythromycin on the pharmacokinetics of lignocaine and its pharmacologically active metabolites in subjects with normal and impaired liver function. Br J Clin Pharmacol 2003; 55: 86-93 [PMID: 12534644]
47. Orlando R, De Martin S, Pegoraro P, Quintieri L, Palatini P. Irreversible CYP3A inhibition accompanied by plasma proteinbinding displacement: A comparative analysis in subjects with normal and impaired liver function. Clin Pharmacol Ther 2009; 85: 319-326 [PMID: 19020496 DOI: 10.1038/clpt.2008.216]
48. Benedetti MS, Whomsley R, Canning M. Drug metabolism in the paediatric population and in the elderly. Drug Discov Today 2007; 12: 599-610 [PMID: 17706541]
49. Le Couteur DG, McLean AJ. The aging liver. Drug clearance and an oxygen diffusion barrier hypothesis. Clin Pharmacokinet 1998; 34: 359-373 [PMID: 9592620 DOI: 10.2165/00003088-19983405 0-00003]
50. Parkinson A, Mudra DR, Johnson C, Dwyer A, Carroll KM. The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicol Appl Pharmacol 2004; 199: 193-209 [PMID: 15364537 DOI: 10.1016/j.taap.2004.01.010]
51. Salem F, Rostami-Hodjegan A, Johnson TN. Do children have the same vulnerability to metabolic drug-drug interactions as adults? A critical analysis of the literature. J Clin Pharmacol 2013; 53: 559-566 [PMID: 23724424]
52. Farrell G. Effects of disease on expression and regulation of CYPs. Mol Aspects Med 1999; 20: 55-70, 137 [PMID: 10575652]
53. Huet PM, Villeneuve JP. Determinants of drug disposition in patients with cirrhosis. Hepatology 1983; 3: 913-918 [PMID: 6629320]
54. Hung DY, Chang P, Cheung K, McWhinney B, Masci PP, Weiss M, Roberts MS. Cationic drug pharmacokinetics in diseased livers determined by fibrosis index, hepatic protein content, microsomal activity, and nature of drug. J Pharmacol Exp Ther 2002; 301: 1079-1087 [PMID: 12023540]
55. Sandson NB, Marcucci C, Bourke DL, Smith-Lamacchia R. An interaction between aspirin and valproate: The relevance of plasma protein displacement drug-drug interactions. Am J Psychiatry 2006; 163: 1891-1896 [PMID: 17074939]
56. Bargetzi MJ, Aoyama T, Gonzalez FJ, Meyer UA. Lidocaine metabolism in human liver microsomes by cytochrome P450IIIA4. Clin Pharmacol Ther 1989; 46: 521-527 [PMID: 2582709]
57. Wang JS, Backman JT, Taavitsainen P, Neuvonen PJ, Kivistö KT. Involvement of CYP1A2 and CYP3A4 in lidocaine N-deethylation and 3-hydroxylation in humans. Drug Metab Dispos 2000; 28: 959-965 [PMID: 10901707]
58. Piafsky KM, Sitar DS, Rangno RE, Ogilvie RI. Theophylline disposition in patients with hepatic cirrhosis. N Engl J Med 1977; 296: 1495-1497 [PMID: 865528]
59. Pieper JA, Johnson KE. Lidocaine. In: Evans WE, Schentag JJ, Jusko WJ, editors. Applied Pharmacokinetics. In: Principles of Therapeutic Drug Monitoring. Vancouver (WA): Applied Therapeutics, 1992: chapter 21
60. Fixley M, Shen DD, Azarnoff DL. Theophylline bioavailability: A comparison of the oral absorption of a theophylline elixir and two combination theophylline tablets to intravenous aminophylline. Am Rev Respir Dis 1977; 115: 955-962 [PMID: 262107]
61. Hendeles L, Weinberger M, Bighley L. Absolute bioavailability of oral theophylline. Am J Hosp Pharm 1977; 34: 525-527 [PMID: 868891]
62. Zhou SF, Xue CC, Yu XQ, Li C, Wang G. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit 2007; 29: 687-710 [PMID: 18043468 DOI: 10.1097/FTD.0b013e31815c16f5]
63. Venkatakrishnan K, Obach RS, Rostami-Hodjegan A. Mechanism-based inactivation of human cytochrome P450 enzymes: strategies for diagnosis and drug-drug interaction risk assessment. Xenobiotica 2007; 37: 1225-1256 [PMID: 17968744 DOI: 10.1080/00498250701670945]
64. Christensen M, Andersson K, Dalén P, Mirghani RA, Muirhead GJ, Nordmark A, Tybring G, Wahlberg A, Yaar U, Bertilsson L. The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes. Clin Pharmacol Ther 2003; 73: 517-528 [PMID: 12811361 DOI: 10.1016/S0009-9236(03)00050-X]
65. Mirghani RA, Ericsson O, Tybring G, Gustafsson LL, Bertilsson L. Quinine 3-hydroxylation as a biomarker reaction for the activity of CYP3A4 in man. Eur J Clin Pharmacol 2003; 59: 23-28 [PMID: 12743670 DOI: 10.1007/s00228-003-0575-5]
66. Wanwimolruk S, Wong SM, Zhang H, Coville PF. Simultaneous determination of quinine and a major metabolite, 3-hydroxyquinine, in biological fluids by HPLC without extraction. J Liq Chromatog Rel Technol 1996; 19: 293-305 [DOI: 10.1080/10826079608005513]
67. Krishna S, White NJ. Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications. Clin Pharmacokinet 1996; 30: 263-299 [PMID: 8983859]
68. Barry M, Keeling PW, Weir D, Feely J. Severity of cirrhosis and the relationship of alpha 1-acid glycoprotein concentration to plasma protein binding of lidocaine. Clin Pharmacol Ther 1990; 47: 366-370 [PMID: 2311337]
69. Routledge PA. The plasma protein binding of basic drugs. Br J Clin Pharmacol 1986; 22: 499-506 [PMID: 3790398]
70. Toutain PL, Bousquet-Melou A. Free drug fraction vs free drug concentration: A matter of frequent confusion. J Vet Pharmacol Ther 2002; 25: 460-463 [PMID: 12485352]
71. Park BK, Kitteringham NR, Pirmohamed M, Tucker GT. Relevance of induction of human drug-metabolizing enzymes: pharmacological and toxicological implications. Br J Clin Pharmacol 1996; 41: 477-491 [PMID: 8799511]
72. Mankowski DC, Ekins S. Prediction of human drug metabolizing enzyme induction. Curr Drug Metab 2003; 4: 381-391 [PMID: 14529370]
73. Tirona RG, Kim RB. Nuclear receptors and drug disposition gene regulation. J Pharm Sci 2005; 94: 1169-1186 [PMID: 15858847 DOI: 10.1002/jps.20324]
74. Lonard DM, O'Malley BW. The expanding cosmos of nuclear receptor coactivators. Cell 2006; 125: 411-414 [PMID: 16678083]
75. Pelkonen O, Turpeinen M, Hakkola J, Honkakoski P, Hukkanen J, Raunio H. Inhibition and induction of human cytochrome P450 enzymes: current status. Arch Toxicol 2008; 82: 667-715 [PMID: 18618097 DOI: 10.1007/s00204-008-0332-8]
76. Willson TM, Brown PJ, Sternbach DD, Henke BR. The PPARs: from orphan receptors to drug discovery. J Med Chem 2000; 43: 527-550 [PMID: 10691680]
77. Huss JM, Kasper CB. Two-stage glucocorticoid induction of CYP3A23 through both the glucocorticoid and pregnane X receptors. Mol Pharmacol 2000; 58: 48-57 [PMID: 10860926]
78. Pascussi JM, Drocourt L, Fabre JM, Maurel P, Vilarem MJ. Dexamethasone induces pregnane X receptor and retinoid X receptor-alpha expression in human hepatocytes: synergistic increase of CYP3A4 induction by pregnane X receptor activators. Mol Pharmacol 2000; 58: 361-372 [PMID: 10908304]
79. Dvorak Z, Pavek P. Regulation of drug-metabolizing cytochrome P450 enzymes by glucocorticoids. Drug Metab Rev 2010; 42: 621-635 [PMID: 20482443 DOI: 10.3109/03602532.2010.484462]
80. Gadaleta RM, Cariello M, Sabbà C, Moschetta A. Tissuespecific actions of FXR in metabolism and cancer. Biochim Biophys Acta 2015; 1851: 30-39 [PMID: 25139561 DOI: 10.1016/ j.bbalip.2014.08.005]
81. Dusso AS, Brown AJ, Slatopolsky E. Vitamin D. Am J Physiol Renal Physiol 2005; 289: F8-28 [PMID: 15951480]
82. Gnerre C, Blättler S, Kaufmann MR, Looser R, Meyer UA. Regulation of CYP3A4 by the bile acid receptor FXR: evidence for functional binding sites in the CYP3A4 gene. Pharmacogenetics 2004; 14: 635-645 [PMID: 15454728]
83. Makishima M, Lu TT, Xie W, Whitfield GK, Domoto H, Evans RM, Haussler MR, Mangelsdorf DJ. Vitamin D receptor as an intestinal bile acid sensor. Science 2002; 296: 1313-1316 [PMID: 12016314 DOI: 10.1126/science.1070477]
84. Lin JH, Lu AY. Interindividual variability in inhibition and induction of cytochrome P450 enzymes. Annu Rev Pharmacol Toxicol 2001; 41: 535-567 [PMID: 11264468]
85. Schue t z EG, Schinke l AH, Re l l ing MV, Schue t z JD. P-glycoprotein: A major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans. Proc Natl Acad Sci USA 1996; 93: 4001-4005 [PMID: 8633005]
86. de Morais SM, Goldstein JA, Xie HG, Huang SL, Lu YQ, Xia H, Xiao ZS, Ile N, Zhou HH. Genetic analysis of the S-mephenytoin polymorphism in a Chinese population. Clin Pharmacol Ther 1995; 58: 404-411 [PMID: 7586932]
87. Lin P, Hu SW, Chang TH. Correlation between gene expression of aryl hydrocarbon receptor (AhR), hydrocarbon receptor nuclear translocator (Arnt), cytochromes P4501A1 (CYP1A1) and 1B1 (CYP1B1), and inducibility of CYP1A1 and CYP1B1 in human lymphocytes. Toxicol Sci 2003; 71: 20-26 [PMID: 12520072]
88. Micka J, Milatovich A, Menon A, Grabowski GA, Puga A, Nebert DW. Human Ah receptor (AHR) gene: localization to 7p15 and suggestive correlation of polymorphism with CYP1A1 inducibility. Pharmacogenetics 1997; 7: 95-101 [PMID: 9170146]
89. Salem SA, Rajjayabun P, Shepherd AM, Stevenson IH. Reduced induction of drug metabolism in the elderly. Age Ageing 1978; 7: 68-73 [PMID: 665427]
90. Dilger K, Hofmann U, Klotz U. Enzyme induction in the elderly: effect of rifampin on the pharmacokinetics and pharmacodynamics of propafenone. Clin Pharmacol Ther 2000; 67: 512-520 [PMID: 10824630]
91. Fromm MF, Dilger K, Busse D, Kroemer HK, Eichelbaum M, Klotz U. Gut wall metabolism of verapamil in older people: effects of rifampicin-mediated enzyme induction. Br J Clin Pharmacol 1998; 45: 247-255 [PMID: 9517368]
92. Gorski JC, Vannaprasaht S, Hamman MA, Ambrosius WT, Bruce MA, Haehner-Daniels B, Hall SD. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity. Clin Pharmacol Ther 2003; 74: 275-287 [PMID: 12966371 DOI: 10.1016/S0009-9236(03)00187-5]
93. Hodek P, Trefil P, Stiborová M. Flavonoids-potent and versatile biologically active compounds interacting with cytochromes P450. Chem Biol Interact 2002; 139: 1-21 [PMID: 11803026]
94. Hoyumpa AM, Schenker S. Major drug interactions: effect of liver disease, alcohol, and malnutrition. Annu Rev Med 1982; 33: 113-149 [PMID: 7044269 DOI: 10.1146/annurev. me.33.020182.000553]
95. Elbekai RH, Korashy HM, El-Kadi AO. The effect of liver cirrhosis on the regulation and expression of drug metabolizing enzymes. Curr Drug Metab 2004; 5: 157-167 [PMID: 15078193]
96. Farrell GC, Zaluzny L. Microsomal protein synthesis and induction of cytochrome P-450 in cirrhotic rat liver. Aust J Exp Biol Med Sci 1984; 62 (Pt 3): 291-301 [PMID: 6497779]
97. Wu ZQ, Piché D, Vallières S, Huet PM, Gascon-Barré M. Unimpaired induction of drug-metabolizing enzymes in hepatocytes isolated from rats with micronodular cirrhosis. Can J Physiol Pharmacol 1991; 69: 426-436 [PMID: 2059906]
98. Joeres R, Klinker H, Heusler H, Epping J, Zilly W, Richter E. Influence of smoking on caffeine elimination in healthy volunteers and in patients with alcoholic liver cirrhosis. Hepatology 1988; 8: 575-579 [PMID: 3371873]
99. Coverdale S, Byth K, Field J, Liddle C, Lin R, Farrell GC. Antipyrine clearance and response to interferon treatment in patients with chronic active hepatitis C. Hepatology 1995; 22: 1065-1071 [PMID: 7557852]
100. Floreani M, De Martin S, Gabbia D, Barbierato M, Nassi A, Mescoli C, Orlando R, Bova S, Angeli P, Gola E, Sticca A, Palatini P. Severe liver cirrhosis markedly reduces AhR-mediated induction of cytochrome P450 in rats by decreasing the transcription of target genes. PLoS One 2013; 8: e61983 [PMID: 23626760 DOI: 10.1371/journal.pone.0061983]
101. Marshall WJ, McLean AE. The effect of cirrhosis of the liver on microsomal detoxications and cytochrome P-450. Br J Exp Pathol 1969; 50: 578-583 [PMID: 5364388]
102. FDA guidance for industry. Pharmacokinetics in patients with impaired hepatic function-study design, data analysis, and impact on dosing and labeling. Rockville (MD): Food and Drug Administration, 1999
103. Capelle P, Dhumeaux D, Mora M, Feldmann G, Berthelot P. Effect of rifampicin on liver function in man. Gut 1972; 13: 366-371 [PMID: 5036092]
104. Farrell GC, Cooksley WG, Powell LW. Drug metabolism in liver disease: activity of hepatic microsomal metabolizing enzymes. Clin Pharmacol Ther 1979; 26: 483-492 [PMID: 487696]
105. De Martin S, Gabbia D, Albertin G, Sfriso MM, Mescoli C, Albertoni L, Paliuri G, Bova S, Palatini P. Differential effect of liver cirrhosis on the pregnane X receptor-mediated induction of CYP3A1 and 3A2 in the rat. Drug Metab Dispos 2014; 42: 1617-1626 [PMID: 25030308 DOI: 10.1124/dmd.114.058511]
106. Choudhuri S, Zhang XJ, Waskiewicz MJ, Thomas PE. Differential regulation of cytochrome P450 3A1 and P450 3A2 in rat liver following dexamethasone treatment. J Biochem Toxicol 1995; 10: 299-307 [PMID: 8934632]
107. Hisaka A, Ohno Y, Yamamoto T, Suzuki H. Prediction of pharmacokinetic drug-drug interactions caused by changes in cytochrome P450 activity using in vivo information. Pharmacol Ther 2010; 125: 230-248 [PMID: 19951720 DOI: 10.1016/j.pharm thera.2009.10.011]
108. FDA Center for Drug Evaluation and Research. Guidance for Industry: Drug Interaction Studies-Study Design, Data Analysis, Implications for Dosing, and Labeling Reccomendations. Rockville (MD): CDER, 2012 Feb [online]. Available from: URL: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ UCM292362.pdf